4/A//SEC Filing
Hannah Brendan 4/A
Accession 0001209191-22-032672
CIK 0001662774other
Filed
May 26, 8:00 PM ET
Accepted
May 27, 5:34 PM ET
Size
5.7 KB
Accession
0001209191-22-032672
Insider Transaction Report
Form 4/AAmended
Cortexyme, Inc.CRTX
Hannah Brendan
CBO, COO and CCO
Transactions
- Award
Common Stock
2022-05-19+113,569→ 129,793 total
Footnotes (2)
- [F1]The shares vest monthly, subject to continued service.
- [F2]On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
Documents
Issuer
Cortexyme, Inc.
CIK 0001662774
Entity typeother
Related Parties
1- filerCIK 0001929422
Filing Metadata
- Form type
- 4/A
- Filed
- May 26, 8:00 PM ET
- Accepted
- May 27, 5:34 PM ET
- Size
- 5.7 KB